Industries > Pharma > Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

Forecasts by Vector Types (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), Application (Antisense & RNAi, Gene Therapy, Cell Therapy, Vaccinology), Disease (Oncology, Genetic Disorders, Infectious Diseases, Others), End-use (Pharma and Biopharma Companies, Research Institutes), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). PLUS Analysis of Leading Viral Vectors & Plasmid DNA Manufacturing Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 24 November 2020
PAGES: 586
PRODUCT CODE: PHA1020
SUBMARKET: Biotechnology

Clear
WOOCS 2.2.1
SKU: PHA1020 Categories: , Tag:

What are the Regulatory Challenges for Viral Vectors for Cell and Gene Therapy?
The processing of viral vectors is complex. It is difficult to scale up legacy technologies adopted from the academic research side, for one thing. Technology issues combined with talent shortages are also a further bottleneck to capacity expansion. The demand for relatively young cells and gene therapy is extremely fragmented worldwide. In order to assist with viral vector demands and shortages, few contract research and development organizations (CMO/CROs) are commercially scaled. Just a handful of larger corporations are capable of manufacturing on a commercial scale, and there are few solutions that enable businesses to increase their own capability.

What are the Technological Advancements in Manufacturing of Viral Vectors?
Gene therapies are incredibly costly in this early stage of growth, but they deliver the promise of being curative in a single phase, thus reducing overall healthcare costs. Many disorders may be treated by recent advances in the discovery of genes responsible for diseases and the use of gene editing technology for genetic modification. As a consequence, biopharmaceutical manufacturers are focused on the rapid market deployment of goods. Their initiatives include designing facilities and supply chains to meet the growing demands of patients worldwide, lowering production costs, the effectiveness and efficacy of these new modalities, and improving patient safety by minimizing the possible side effects of gene therapy drugs.

UNIQUE COVID-19 VARIATIONS– only available in this Visiongain report are dedicated analysis of 4 different rebound scenarios of how the market will develop – no matter how COVID-19 affects the economy.

To access the data contained in this document please email contactus@visiongain.com

Which Factors are Fueling Viral Vectors and Plasmid DNA Manufacturing Industry Growth?
– Robust Pipeline for Gene Therapy and Viral Vectors
– Increasing Capacities by Manufacturers Owing to Rising Demand

Which Factors are Restraining Growth?
– High Cost of Therapies
– Bottlenecks Experienced by Manufacturers

What are the Market Opportunities & Threats?
– Rise in the Development of Allogenic and Autologous Cell Therapy
– Lucrative opportunity in manufacturing of COVID-19 vaccine
– Increasing Applications as Preclinical Tool in Neuroscience Research

How do prominent players strengthen their position throughout the world?
You must read this newly updated report if you are involved in this sector. The report from Visiongain shows you potential revenues up to 2031, evaluate information, trends, opportunities and business outlooks.

Discover how to stay ahead
Our 580+ page report provides 500+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Viral Vectors and Plasmid DNA Manufacturing Market. See how to exploit the opportunities.

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, Porter’s Analysis, product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Vector Type
• Adenovirus
• Retrovirus
• Plasmid DNA
• AAV
• Lentivirus
• Others

Application
• Antisense & RNAi
• Gene Therapy
• Cell Therapy
• Vaccinology

Disease
• Oncology
• Genetic Disorders
• Infectious Diseases
• Others

End-Use
• Pharma and Biopharma Companies
• Research Institutes

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 9 leading national markets:

By Region

• North America
– U.S.
– Canada

• Europe
– Germany
– UK
– Rest of Europe

• Asia Pacific
– China
– Japan
– India
– Rest of Asia Pacific

• Latin America
– Brazil
– Rest of Latin America

• Middle East and Africa
– South Africa
– Rest of MEA

Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

Need industry data? Please contact us today.

Leading companies and the potential for market growth
Overall world revenue for Viral Vectors and Plasmid DNA Manufacturing Market will surpass $xx million in 2020, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which regions hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Prospects for established firms and those seeking to enter the market– including company profiles for 32 of the major companies involved in the Viral Vectors and Plasmid DNA Manufacturing Market. Some of the companies profiled in this report include Merck KGaA, Lonza, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Cobra Biologics Ltd., Brammer Bio, Waisman Biomanufacturing, Genezen, YPOSKESI, Advanced BioScience Laboratories, Inc. (ABL, Inc.), Novasep Holding S.A.S, ATVIO Biotech Ltd, Vigene Biosciences, Inc., Cytiva, CEVEC Pharmaceuticals GmbH, Batavia Biosciences B.V, Biovian Oy, Wuxi AppTec Co., Ltd., VGXI, Inc., Paragon Bioservices, Inc., Miltenyi Biotec GmbH, SIRION Biotech GmbH, Virovek Incorporation, BioNTech IMFS GmbH, VIVEbiotech S.L., Creative Biogene, Vibalogics GmbH, Cell and Gene Therapy Catapult, BlueBird Bio, Addgene, Inc., Aldevron, L.L.C., Audentes Therapeutics, and BioMarin Pharmaceutical.

Key Questions Answered by this Report:
– What is the current size of the overall global viral vectors and plasmid DNA manufacturing market? How much will this market be worth from 2021 to 2031?
– What are the main drivers and restraints that will shape the overall viral vectors and plasmid DNA manufacturing market over the next ten years?
– What are the main segments within the overall viral vectors and plasmid DNA manufacturing market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why?
– What factors will affect that industry and market over the next ten years?
– What are the largest national markets for the world viral vectors and plasmid DNA manufacturing? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2031?
– How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
– Which are the leading companies and what are their activities, results, developments, and prospects?
– What are the main trends that will affect the world Viral Vectors and Plasmid DNA Manufacturing market between 2021 and 2031?
– What are the main strengths, weaknesses, opportunities, and threats for the market?
– How will the global viral vectors and plasmid DNA manufacturing market evolve over the forecasted period, 2021 to 2031?
– How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.

Visiongain’s study is intended for everybody needing commercial analyses for the Global Viral Vectors and Plasmid DNA Manufacturing Market and leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031: Forecasts by Vector Types (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), Application (Antisense & RNAi, Gene Therapy, Cell Therapy, Vaccinology), Disease (Oncology, Genetic Disorders, Infectious Diseases, Others), End-use (Pharma and Biopharma Companies, Research Institutes), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). PLUS Analysis of Leading Viral Vectors & Plasmid DNA Manufacturing Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031


Download sample pages

Complete the form below to download your free sample pages for Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031


Latest Pharma news

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

READ

Visiongain Publishes Inhalation & Nasal Spray Generic Drugs Market Report 2021-2031

Rising prevalence of chronic respiratory diseases including asthma, COPD, and allergic rhinitis; rising geriatric population, escalating investment in drug R&D by biopharmaceutical & pharmaceutical companies; growing respiratory health care awareness; and new product launches worldwide are some of the major factors that boosting the growth of global inhalation & nasal spray generic drugs market.

31 March 2021

READ

Categories